Berenberg Bank analyst Zhiqiang Shu maintained a Hold rating on Sensei Biotherapeutics (SNSE – Research Report) on October 7 and set a price target of $6.00. The company’s shares closed yesterday at $1.54.
Shu covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Arcus Biosciences, and BioNTech SE. According to TipRanks, Shu has an average return of -28.2% and a 17.57% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sensei Biotherapeutics with a $5.50 average price target.
See today’s best-performing stocks on TipRanks >>
SNSE market cap is currently $47.62M and has a P/E ratio of -1.12.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sensei Biotherapeutics Inc is a clinical-stage immunotherapy company. It is engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. The companies ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response.
Read More on SNSE:
- Sensei Biotherapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Oppenheimer upgrades Sensei Biotherapeutics to Outperform with $5 price target
- Sensei Biotherapeutics upgraded to Outperform from Perform at Oppenheimer
- Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
